Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.43 |
| ▸ | CASR | P41180 | 4/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | COASY | Q13057 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11746688 | 0.91 | SLC6A2 (0.41) | ADRB2ADRB1ADRB3SLC2A1CASR | |
| SCHEMBL13137654 | 0.86 | CASR (0.43) | ADRB2ADRB1ADRB3SLC2A1CASR | |
| SCHEMBL12652270 | 0.84 | ADRB2 (0.43) | ADRB2ADRB1ADRB3SLC2A1CASR | |
| SCHEMBL9004208 | 0.81 | CASR (0.42) | ADRB2ADRB1ADRB3SLC2A1CASR | |
| SCHEMBL28277765 | 0.80 | COASY (0.46) | ADRB2ADRB1ADRB3SLC2A1CASR | |
| SCHEMBL15247597 | 0.80 | COASY (0.46) | ADRB2ADRB1ADRB3SLC2A1CASR | |
| SCHEMBL8222529 | 0.80 | POLB (0.44) | ADRB2ADRB1ADRB3SLC2A1CASR | |
| SCHEMBL28373273 | 0.80 | ADRB3 (0.47) | ADRB2ADRB1ADRB3SLC2A1 | |
| SCHEMBL27351455 | 0.79 | ADRB2 (0.43) | ADRB2ADRB1ADRB3SLC2A1AOC3 | |
| SCHEMBL178548 | 0.79 | COASY (0.44) | ADRB2ADRB1ADRB3SLC2A1CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124634-B2 | CB1 receptor modulators | 7TM PHARMA A/S (DK) | 2012-02-28 | — | — | US | disclosed |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA A/S (DK) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | CNR1, CNR2, GPR6 | ADRB2 171/4885ADRB1 145/4885ADRB3 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.